Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

Y0000666

Terazosin for system suitability

CRS, European Pharmacopoeia (EP) Reference Standard

Synonyma:

Terazosin hydrochloride dihydrate, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride dihydrate

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C19H25N5O4 · HCl · 2H2O
Číslo CAS:
70024-40-7
Molekulová hmotnost:
459.92
MDL number:
MFCD00941408
UNSPSC Code:
41116107
PubChem Substance ID:
329831082
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

terazosin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.O.Cl.COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

InChI key

NZMOFYDMGFQZLS-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

Terazosin hydrochloride is a quinazoline derivative. It is a alpha-1-selective adrenoceptor blocking agent. It has been used to treat hypertension, as it helps the blood vessels to relax, expand and improves blood flow.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

It may be used as drug standard stock solution for determination of terazosin hydrochloride dihydrate using potentiometric and fluorimetric techniques.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

Y0000622

Terazosin impurity A, European Pharmacopoeia (EP) Reference Standard

1643463

Terazosin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1643474

Terazosin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1643485

Terazosin Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0000621

Terazosin hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0000665

Terazosin impurity E, European Pharmacopoeia (EP) Reference Standard

Y0000624

Terazosin impurity N, European Pharmacopoeia (EP) Reference Standard

1643452

Terazosin hydrochloride, United States Pharmacopeia (USP) Reference Standard

PHR1721

Terazosin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

Y0002286

Terazosin for system suitability A, European Pharmacopoeia (EP) Reference Standard

PHR3137

Terazosin Related Compound A, certified reference material, pharmaceutical secondary standard

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H319

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

M R Yadav et al.
Pharmaceutical biology, 50(4), 439-442 (2011-12-06)
The problem of hypertension has gained enormous proportions in the past decade. Multifactorial etiology and complex pathophysiology of the disease has rendered the treatment of the disease a hard task. Sympathetic nervous system and the renin-angiotensin-aldosterone system are primary contributors
Gholamreza Mokhtari et al.
Urologia internationalis, 87(1), 19-22 (2011-05-21)
We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents. In this double-blind randomized clinical trial, 73 patients with unilateral ureteral stone and hydroureteronephrosis who underwent insertion
Man Liu et al.
Chirality, 24(12), 1047-1050 (2012-08-14)
The purpose of this study was to elucidate the pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. After a single oral dose of 2-mg terazosin, the plasma concentrations of terazosin enantiomers were measured over the course of 48 h
Laurel E Ecke et al.
Neuroreport, 23(5), 325-330 (2012-02-18)
The rewarding properties of psychomotor stimulants are traditionally thought to be independent of norepinephrine. Recent findings, however, suggest that local noradrenergic signaling through α1 receptors in the medial prefrontal cortex and the ventral tegmental area - brain regions critically important
Stephanie C Lazzaro et al.
Learning & memory (Cold Spring Harbor, N.Y.), 17(10), 489-493 (2010-09-28)
Norepinephrine receptors have been studied in emotion, memory, and attention. However, the role of alpha1-adrenergic receptors in fear conditioning, a major model of emotional learning, is poorly understood. We examined the effect of terazosin, an alpha1-adrenergic receptor antagonist, on cued
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.